NDA 014879 · Hikma
Dopram
Doxapram Hydrochloride · Injection
NovelLast checked: Nov 20, 2026Latest source record: Mar 29, 2006 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1965
Jun 23, 1965
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
1 Phase 3, 2 recruiting
FAERS reports
22
21 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 8, 2025.
INDICATIONS & USAGE Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE & ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 23, 1965 Original approval · Type 1 - New Molecular Entity
1 products under this application
- DOPRAM · DOXAPRAM HYDROCHLORIDE 20MG/ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Doxapram" as an intervention, any sponsor and status, largest first.
- Doxapram Therapy in Preterm Infants (DOXA Trial)Pivotal-lookingRecruiting
Erasmus Medical CenterAcademic, hospital or other
NCT04430790 · 396 participants (planned) · Start Jun 15, 2020 · Primary completion May 1, 2026
Drug: Doxapram; Placebo · For: Apnea of Prematurity; Respiratory Insufficiency
Sites: Brussels, Belgium; Jette, Belgium; Charleroi, Belgium · 24 sites in all
- Aminophylline and Cognitive Function After Sevoflurane AnaesthesiaPivotal-lookingCompleted
King Faisal UniversityAcademic, hospital or other
NCT01022151 · 180 participants · Start Nov 2007 · Primary completion Jul 2010
Drug: Placebo [group P]; 0.2 mL/kg of aminophylline 10 mg/mL [group A2] and 4 more · For: Anaesthesia
Sites: Khobar, Saudi Arabia
Jean Michel HascoetAcademic, hospital or other
NCT00389909 · 85 participants · Start Nov 2006 · Primary completion Nov 2010
Drug: Doxapram · For: Premature Infants; Apnea
Sites: Nancy, France; Toulouse, France
Beni-Suef UniversityAcademic, hospital or other
NCT03894189 · 70 participants (planned) · Start May 2019 · Primary completion Dec 2019
Drug: Doxapram Hydrochloride; Theophylline · For: Weaning Failure
Sites: Banī Suwayf, Egypt
- the Effect of Doxapram on Diaphragmatic Excursion(DE) During Weaning From Mechanical Ventilation.Not yet recruiting
Kasr El Aini HospitalAcademic, hospital or other
NCT07637149 · 60 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 1, 2026
Drug: Doxapram · For: Mechanically Ventilated ICU Patients; Diaphragm Excursion
Helsinki University Central HospitalAcademic, hospital or other
NCT02171910 · 50 participants · Start Oct 2016 · Primary completion Dec 2016
Drug: Doxapram; Placebo · For: Sedation; Hypoxia
Sites: Helsinki, Finland
- Staccato Alprazolam in Panic AttackCompleted
Alexza Pharmaceuticals, Inc.Not stated
NCT00477451 · 49 participants · Start May 2007 · Primary completion Apr 2008
Drug: Inhaled placebo; Inhaled alprazolam 1 mg and 2 more · For: Treatment of Induced Panic Attack
Sites: Brooklyn, New York; New York, New York · 3 sites in all
General Hospital of Ningxia Medical UniversityAcademic, hospital or other
NCT02820025 · 40 participants · Start Oct 2015 · Primary completion Apr 2017
Drug: doxapram · For: Anesthesia
Sites: Yinchuan, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- depressed level of consciousness5
- atrial fibrillation4
- respiratory failure4
- electrocardiogram qt prolonged3
- hepatic failure3
- hepatitis fulminant3
- bradycardia2
- cardiac failure2
- delayed recovery from anaesthesia2
- ejection fraction decreased2
- hypokalaemia2
- hypoxia2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 2 |
| 2006 | 3 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2020 | 2 |
| 2023 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxapram treatment for apnea in preterm infants.
Henderson-Smart D, Steer P · Cochrane Database Syst Rev 2004 · Systematic Review
- Doxapram Treatment for Apnea of Prematurity: A Systematic Review.
Vliegenthart RJ, Ten Hove CH, Onland W, et al. · Neonatology 2017 · Meta-Analysis, Systematic Review
- Doxapram treatment for apnea in preterm infants.
Henderson-Smart DJ, Steer PA · Cochrane Database Syst Rev 2001 · Systematic Review
- Doxapram and perception of dyspnea.
Ebihara S, Ogawa H, Sasaki H, et al. · Chest 2002 · Clinical Trial, Letter
- Doxapram versus methylxanthine for apnea in preterm infants.
Henderson-Smart DJ, Steer P · Cochrane Database Syst Rev 2000 · Systematic Review
- Periextubation caffeine in preterm neonates: a randomized dose response trial.
Steer PA, Flenady VJ, Shearman A, et al. · J Paediatr Child Health 2003 · Clinical Trial, Randomized Controlled Trial
Sponsor: Hikma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.